scholarly journals Managing Myocardial Injury after Noncardiac Surgery in End Stage Renal Disease: A Clinical Challenge

2021 ◽  
Vol 16 (3) ◽  
pp. 2-3
Author(s):  
Flavia Borges ◽  
Sandra Ofori ◽  
Maura Marcucci
Keyword(s):  
Atrial Fibrillation ◽  
Clinical Practice ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Myocardial Injury ◽  
Noncardiac Surgery ◽  
Clinical Challenge ◽  
Stage Renal Disease ◽  
End Stage

RE: Myocardial injury after noncardiac surgery and perioperative atrial fibrillation: From evidence to clinical practice

scholarly journals Anticoagulation in Patients with End-Stage Renal Disease and Atrial Fibrillation: Confusion, Concerns and Consequences

2020 ◽  
Vol 22 (3) ◽  
pp. 306-316
Author(s):  
Narender Goel ◽  
Deepika Jain ◽  
Danny B. Haddad ◽  
Divya Shanbhogue
Keyword(s):  
Atrial Fibrillation ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Clinical Decision Making ◽  
Controlled Trial ◽  
Oral Anticoagulants ◽  
Increased Risk ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

End-stage renal disease (ESRD) patients have a higher prevalence of diabetes mellitus, hypertension, congestive heart failure and advanced age, along with an increased incidence of non-valvular atrial fibrillation (AF), thereby increasing the risk for cerebrovascular accidents. Systemic anticoagulation is therefore recommended in patients with ESRD with AF to reduce the risk and complications from thromboembolism. Paradoxically, these patients are at an increased risk of bleeding due to great degree of platelet dysfunction and impaired interaction between platelet and endothelium. Currently, CHA2DS2-VASc and Hypertension, Abnormal liver/kidney function, Stroke, Bleeding, Labile INR, Elderly, Drugs or alcohol (HAS-BLED) are the recommended models for stroke risk stratification and bleeding risk assessment in patients with AF. There is conflicting data regarding benefits and risks of medications such as antiplatelet agents, warfarin and direct oral anticoagulants in ESRD patients with AF. Moreover, there is no randomized controlled trial data to guide the clinical decision making. Hence, a multi-disciplinary approach with annual re-evaluation of treatment goals and risk-benefit assessment has been recommended. In this article, we review the current recommendations with risks and benefits of anticoagulation in patients with ESRD with AF.

scholarly journals Treatment of atrial fibrillation with warfarin among older adults with end stage renal disease

2017 ◽  
Vol 30 (6) ◽  
pp. 831-839 ◽  
Author(s):  
Jingwen Tan ◽  
Sunjae Bae ◽  
Jodi B. Segal ◽  
Junya Zhu ◽  
Dorry L. Segev ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Older Adults ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies

2002 ◽  
Vol 283 (6) ◽  
pp. F1167-F1175 ◽  
Author(s):  
Roberto Zatz ◽  
Irene Lourdes Noronha ◽  
Clarice Kazue Fujihara
Keyword(s):  
Mycophenolate Mofetil ◽  
Clinical Practice ◽  
Renal Disease ◽  
Renal Injury ◽  
End Stage Renal Disease ◽  
Allograft Rejection ◽  
Immune Mediated ◽  
Stage Renal Disease ◽  
End Stage ◽  
Inflammatory Action

The incidence of progressive nephropathies and, consequently, the population suffering from end-stage renal disease have increased steadily in recent years, posing an ever-growing cost, in both human and financial terms, to society. There is mounting evidence that, in both immune-mediated and nonimmune-mediated chronic nephropathies, renal inflammatory events are key to the propagation and perpetuation of renal injury. Mycophenolate mofetil (MMF) is an antilymphocyte agent recently introduced in clinical practice for the prevention of allograft rejection. The present review discusses clinical and experimental evidence that the anti-inflammatory action of MMF can be advantageously used to arrest immune- and nonimmune-mediated progressive injury of native kidneys as well.

Sign in / Sign up

Export Citation Format

Share Document